NasdaqGM:AKBA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Akebia Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AKBA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: AKBA's weekly volatility has increased from 17% to 23% over the past year.


Market Performance


7 Day Return

18.1%

AKBA

-0.1%

US Biotechs

-0.06%

US Market


1 Year Return

-37.0%

AKBA

22.0%

US Biotechs

19.0%

US Market

Return vs Industry: AKBA underperformed the US Biotechs industry which returned 22% over the past year.

Return vs Market: AKBA underperformed the US Market which returned 19% over the past year.


Shareholder returns

AKBAIndustryMarket
7 Day18.1%-0.1%-0.06%
30 Day-3.5%5.8%4.4%
90 Day-69.8%6.3%6.3%
1 Year-37.0%-37.0%24.1%22.0%21.7%19.0%
3 Year-80.3%-80.3%24.2%17.9%46.4%36.7%
5 Year-71.4%-71.4%11.2%3.5%91.0%69.9%

Long-Term Price Volatility Vs. Market

How volatile is Akebia Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Akebia Therapeutics undervalued compared to its fair value and its price relative to the market?

1.38x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AKBA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AKBA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AKBA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AKBA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AKBA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AKBA is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Akebia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

61.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKBA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKBA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKBA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKBA's revenue (5% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: AKBA's revenue (5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AKBA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Akebia Therapeutics performed over the past 5 years?

-33.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AKBA is currently unprofitable.

Growing Profit Margin: AKBA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AKBA is unprofitable, and losses have increased over the past 5 years at a rate of 33.6% per year.

Accelerating Growth: Unable to compare AKBA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKBA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.2%).


Return on Equity

High ROE: AKBA has a negative Return on Equity (-122.95%), as it is currently unprofitable.


Next Steps

Financial Health

How is Akebia Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AKBA's short term assets ($391.0M) exceed its short term liabilities ($181.5M).

Long Term Liabilities: AKBA's short term assets ($391.0M) exceed its long term liabilities ($176.7M).


Debt to Equity History and Analysis

Debt Level: AKBA's debt to equity ratio (24.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AKBA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKBA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AKBA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Akebia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AKBA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AKBA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AKBA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKBA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AKBA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

John Butler (56 yo)

7.17yrs

Tenure

US$4,316,964

Compensation

Mr. John P. Butler, MBA, has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013. Mr. Butler served as Chief Executive Officer of Inspiration Biopharmaceuticals...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD4.32M) is above average for companies of similar size in the US market ($USD1.81M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Butler
CEO, President & Director7.17yrsUS$4.32m0.63%
$ 2.8m
Michel Dahan
Senior VP & COOno dataUS$1.49m0.067%
$ 296.6k
Nicole Hadas
Senior VP7.83yrsUS$1.42m0.074%
$ 329.8k
Jason Amello
Executive Officer0.42yrUS$1.50m0.049%
$ 218.9k
Dell Faulkingham
Senior VP & Chief Commercial Officer1.5yrsUS$1.39m0.013%
$ 57.0k
David Spellman
Senior VP0.42yrno datano data
Kristen Sheppard
Vice President of Investor Relationsno datano datano data
Douglas Jermasek
Vice President of Marketing & Strategyno datano datano data
Tamara Dillon
Senior Vice President of Human Resources4yrsno datano data
Karen Tubridy
Senior VP & Chief Development Officer4yrsno data0.024%
$ 106.5k
Steven Burke
Senior VP & Chief Medical Officer1.25yrsno data0.019%
$ 82.9k
Michael Rabinowitz
Vice President of Researchno datano datano data

2.8yrs

Average Tenure

49.5yo

Average Age

Experienced Management: AKBA's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Butler
CEO, President & Director7.17yrsUS$4.32m0.63%
$ 2.8m
Suzette Dutch
Observerno datano datano data
Michael Rogers
Independent Director1.92yrsUS$170.97k0.0078%
$ 34.5k
Peter Hutt
no datano datano data
Adrian Adams
Independent Chairperson1.92yrsUS$195.97k0.044%
$ 195.6k
Maxine Gowen
Independent Director6.33yrsUS$170.29k0.0072%
$ 32.0k
Randall Johnson
Advisor & Member of Scientific Advisory Boardno datano datano data
John Adamson
no datano datano data
Frank Bunn
no datano datano data
Volker Haase
Advisor & Member of Scientific Advisory Boardno datano datano data
Sean Colgan
Member of Scientific Advisory Boardno datano datano data
Cynthia Smith
Independent Director2.25yrsUS$166.92k0.017%
$ 74.1k

2.3yrs

Average Tenure

62yo

Average Age

Experienced Board: AKBA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.5%.


Top Shareholders

Company Information

Akebia Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Akebia Therapeutics, Inc.
  • Ticker: AKBA
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$443.734m
  • Shares outstanding: 144.54m
  • Website: https://www.akebia.com

Number of Employees


Location

  • Akebia Therapeutics, Inc.
  • 245 First Street
  • Suite 1400
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AKBANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMar 2014
AX9DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2014

Biography

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company’s lead product candidate includ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/23 23:55
End of Day Share Price2020/11/23 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.